Our Culture of Caring: Volunteering
At BI we are committed to improving the health and well-being of people & animals. We encourage & support employee volunteer activities.
Search
Livestock
Livestock
Heart Diseases
Heart Diseases
Pets
Pets
Boehringer Ingelheim Advances Novel Bi-specific TRAILR2/CDH17 Antibody to Phase 1 Clinical Trial for Patients Living with Gastrointestinal Cancers
Boehringer Ingelheim Advances Novel Bi-specific TRAILR2/CDH17 Antibody to Phase 1 Clinical Trial for Patients Living with Gastrointestinal Cancers
Boehringer Ingelheim Collaborates with Proxygen to Explore Molecular Glue Degraders - a Novel Approach to Fight Cancer
Boehringer Ingelheim Collaborates with Proxygen to Explore Molecular Glue Degraders - a Novel Approach to Fight Cancer
Outlook for Partnering in Animal Health 2024
Megan Grether, Head of Business Development & Licensing for Animal Health, shares her perspectives on the year ahead for partnering in Animal Health.
Boehringer Ingelheim acquires Abexxa Biologics to further expand its research efforts in cancer immunology and novel immunotherapeutic approaches
Boehringer Ingelheim acquires Abexxa Biologics to further expand its research efforts in cancer immunology and novel immunotherapeutic approaches
Our Mission
Our Story
Boehringer Ingelheim Expands KRAS Cancer Program with Lupin’s Clinical Stage MEK Inhibitor Compound
Boehringer Ingelheim Expands KRAS Cancer Program with Lupin’s Clinical
Boehringer Ingelheim’s Carine Boustany Appointed to BIO Board
Boehringer Ingelheim’s Carine Boustany Appointed to BIO Board
From garage start-up to global pharma: combining strengths to advance regenerative medicine
Article describing how a strategic partnership between Global Stem Cell and Boehringer Ingelheim Animal Health has played a key role in helping the companies accelerate breakthroughs in regenerative medicine.
Quantum Computing: Boehringer Ingelheim and Google Partner for Pharma R&D
Quantum Computing: Boehringer Ingelheim and Google Partner for Pharma R&D
Boehringer Ingelheim Animal Health USA Establishes Pawru, Inc.
Boehringer Ingelheim Animal Health USA Establishes Pawru, Inc.
Boehringer Ingelheim and OSE Immunotherapeutics Announce Global Immuno-Oncology Partnership to Develop a Pioneering Checkpoint Inhibitor for the Treatment of Advanced Solid Tumors
Boehringer Ingelheim and OSE Immunotherapeutics Announce Global Immuno-Oncology Partnership to Develop a Pioneering Checkpoint Inhibitor for the Treatment of Advanced Solid Tumors
Boehringer Ingelheim Acquires AMAL Therapeutics
Boehringer Ingelheim Acquires AMAL Therapeutics
FDA Grants BTD for Investigational Treatment of CIAS | BI US
Learn about the breakthrough therapy designation grant for BI's latest investigational treatment of cognitive impairment associated with schizophrenia.
Schizophrenia: Trial Results Show Advance in Cognition | BI US
Boehringer Ingelheim today announced the results from a 12-week, placebo-controlled Phase II trial, that demonstrate BI 425809 met its primary endpoint.
Our Work with the Gates Foundation | COVID-19 | Boehringer Ingelheim US
With global life science companies, we are joining the COVID-19 Therapeutics Accelerator of the Bill & Melinda Gates Foundation to fight the pandemic.
Digital solutions save lives
Digital solutions save lives
Ensuring Global Access to Corona Care | Boehringer Ingelheim US
BI has signed a communiqué with the Bill & Melinda Gates Foundation and 15 other companies committing to provide access to COVID-19 related services.
Boehringer Ingelheim Announces U.S. Country Managing Director Jean-Michel Boers Appointed to PhRMA Board of Directors
Boehringer Ingelheim Announces U.S. Country Managing Director Jean-Michel Boers Appointed to PhRMA Board of Directors
Oncology & Cancer Immunology
Oncology & Cancer Immunology
Boehringer Ingelheim and MD Anderson Expand Collaboration to Accelerate Development of KRAS and TRAILR2 Compounds in Lung Cancer
Boehringer Ingelheim and MD Anderson Expand Collaboration to Accelerate Development of KRAS and TRAILR2 Compounds in Lung Cancer
Boehringer Ingelheim enters into collaboration with Roche to partner for inflammatory bowel diseases
Boehringer Ingelheim enters into collaboration with Roche to partner for inflammatory bowel diseases